Immunic to raise $400M for late-stage MS trials and commercial launch
Immunic plans to raise up to $400 million to advance its late-stage multiple sclerosis clinical program. The financing will fund pivotal MS trials and support commercial launch preparations for its lead therapy.
1. Financing Structure
Immunic plans to raise up to $400 million through a public offering of securities, providing fresh capital to its balance sheet. The company intends to use the proceeds to extend its cash runway into key upcoming milestones.
2. Late-Stage MS Trials Funding
Proceeds are earmarked to support ongoing and planned pivotal studies in multiple sclerosis, accelerating patient enrollment and data readouts. This funding aims to ensure uninterrupted progress of its lead candidate through regulatory review.
3. Commercial Launch Preparations
A portion of the funds will be allocated to build out commercial capabilities, including manufacturing scale-up, market access planning and sales infrastructure. These activities are designed to position the therapy for a potential U.S. and European launch upon approval.